Adoptively transferred T-cells can prolong survival and sometimes cure patients with advanced solid tumors. While promising, it can take months to generate the necessary T-cells to help these patients. Such slow speed makes this therapy impractical for most patients who need immediate treatment. In the September issue of Cancer Research, Hannah Knochelmann, a student in… Read More »
Researchers at Trinity College Dublin have identified a so-called “executioner cell” that may hold the key to eventually finding a treatment to slow retinal degeneration that causes blindness in millions of people each year. A multi-disciplinary team involving experts from TCD believe they have pinpointed a potential new therapeutic target for treating retinal degeneration. It… Read More »
Juul pod flavors like creme brulee, menthol and mint blamed for getting teens hooked on vaping raise risks for lung injuries and cancer by damaging DNA, study suggests Sweet e-cigarette liquid flavors have been blamed for getting teenagers addicted to vaping But little is known about how the chemicals in these flavors may affect the… Read More »
Novartis’ big push into cell and gene therapy hasn’t been the smoothest of rides, with a data manipulation scandal hamstringing Zolgensma and manufacturing concerns hurting CAR-T cancer therapy Kymriah. Could a new European facility help turn around the latter’s production bottleneck? Novartis last week opened its newest cell and gene therapy facility in Stein, Switzerland,… Read More »
FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions Print this page SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the… Read More »